US stock trading volume rankings change: Storage giants take first and third place, SanDisk surpasses many star stocks

金色财经2026/06/22 15:15

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Jinse Finance reported that as of June 22, at the time of publication, SanDisk's stock price rose by 6.2% to $2,319.26 per share, once again reaching a record high. The trading volume reached 8.9 billion USD, ranking third among all stocks in the US market, second only to a certain exchange and SpaceX. It even surpassed well-known companies such as a certain exchange, Tesla, Intel, AMD, Google, and Microsoft, indicating that capital is rapidly concentrating in the semiconductor sub-sector. A certain exchange topped the list with a trading volume of 21.386 billion USD and its stock price rose by 4.71% on the day. Although SpaceX ranked second, its stock price plummeted by 10.65%, with a trading volume of 9.534 billion USD, showing obvious market divergence. The current US stock market is characterized by "high trading volume and high volatility". On one hand, the long-term logic of the AI industry remains unchanged; on the other hand, capital has begun to reassess the profitability of niche sectors. In the near future, storage chips, advanced manufacturing, and innovative pharmaceuticals could continue to be major directions for capital competition.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)

路透社•2026/10/06 07:26